JP6792875B2 - Hbed−ビスホスホネート、その放射性金属コンジュゲート、およびセラノスティック剤としてのそれらの使用 - Google Patents

Hbed−ビスホスホネート、その放射性金属コンジュゲート、およびセラノスティック剤としてのそれらの使用 Download PDF

Info

Publication number
JP6792875B2
JP6792875B2 JP2017568376A JP2017568376A JP6792875B2 JP 6792875 B2 JP6792875 B2 JP 6792875B2 JP 2017568376 A JP2017568376 A JP 2017568376A JP 2017568376 A JP2017568376 A JP 2017568376A JP 6792875 B2 JP6792875 B2 JP 6792875B2
Authority
JP
Japan
Prior art keywords
group
pharmaceutically acceptable
acceptable salt
complex
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017568376A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018524352A (ja
JP2018524352A5 (enExample
Inventor
ハンク エフ. クン,
ハンク エフ. クン,
ゼフイ ウー,
ゼフイ ウー,
ソク レ チェ,
ソク レ チェ,
カール プレスル,
カール プレスル,
ジハオ ジャ,
ジハオ ジャ,
Original Assignee
ファイブ イレブン ファーマ インコーポレイテッド
ファイブ イレブン ファーマ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファイブ イレブン ファーマ インコーポレイテッド, ファイブ イレブン ファーマ インコーポレイテッド filed Critical ファイブ イレブン ファーマ インコーポレイテッド
Publication of JP2018524352A publication Critical patent/JP2018524352A/ja
Publication of JP2018524352A5 publication Critical patent/JP2018524352A5/ja
Application granted granted Critical
Publication of JP6792875B2 publication Critical patent/JP6792875B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839Polyphosphonic acids
    • C07F9/3873Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0489Phosphates or phosphonates, e.g. bone-seeking phosphonates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0497Organic compounds conjugates with a carrier being an organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/003Compounds containing elements of Groups 3 or 13 of the Periodic Table without C-Metal linkages
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3808Acyclic saturated acids which can have further substituents on alkyl
    • C07F9/3817Acids containing the structure (RX)2P(=X)-alk-N...P (X = O, S, Se)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6515Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having three nitrogen atoms as the only ring hetero atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6524Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having four or more nitrogen atoms as the only ring hetero atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Radiology & Medical Imaging (AREA)
  • Steroid Compounds (AREA)
JP2017568376A 2015-07-07 2016-07-06 Hbed−ビスホスホネート、その放射性金属コンジュゲート、およびセラノスティック剤としてのそれらの使用 Active JP6792875B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562189652P 2015-07-07 2015-07-07
US62/189,652 2015-07-07
US201662320296P 2016-04-08 2016-04-08
US62/320,296 2016-04-08
PCT/US2016/041040 WO2017007790A1 (en) 2015-07-07 2016-07-06 Hbed-bisphosphonates, radiometal conjugates thereof and their use as theranostic agents

Publications (3)

Publication Number Publication Date
JP2018524352A JP2018524352A (ja) 2018-08-30
JP2018524352A5 JP2018524352A5 (enExample) 2019-07-25
JP6792875B2 true JP6792875B2 (ja) 2020-12-02

Family

ID=57685907

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017568376A Active JP6792875B2 (ja) 2015-07-07 2016-07-06 Hbed−ビスホスホネート、その放射性金属コンジュゲート、およびセラノスティック剤としてのそれらの使用

Country Status (12)

Country Link
US (1) US10253052B2 (enExample)
EP (1) EP3319643B1 (enExample)
JP (1) JP6792875B2 (enExample)
KR (1) KR102651945B1 (enExample)
CN (1) CN107847618B (enExample)
AU (1) AU2016289474C1 (enExample)
CA (1) CA2991498A1 (enExample)
DK (1) DK3319643T3 (enExample)
EA (1) EA201890221A1 (enExample)
IL (1) IL256726A (enExample)
MX (1) MX377208B (enExample)
WO (1) WO2017007790A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX377208B (es) 2015-07-07 2025-03-07 Five Eleven Pharma Inc Bifosfonatos de hbed, sus conjugados radio metalicos y su uso como agentes teranosticos.
TW201832750A (zh) * 2017-03-02 2018-09-16 美商511製藥公司 放射性藥品標記裝置
WO2020028825A1 (en) * 2018-08-03 2020-02-06 Board Of Regents, The University Of Texas System Method for extraction and purification of 68ga
CN109438517B (zh) * 2018-12-27 2021-01-08 北京久杰净化工程技术有限公司 一种与羰基金属核心配位的双功能连接剂的配合物及其制备方法
CA3137963A1 (en) * 2019-04-26 2020-10-29 Five Eleven Pharma Inc. Prostate-specific membrane antigen (psma) inhibitors as diagnostic and radionuclide therapeutic agents
WO2021067513A1 (en) * 2019-10-01 2021-04-08 City Of Hope Metal chelating agents and methods of using the same
DE102021101216A1 (de) * 2021-01-21 2022-07-21 Johannes Gutenberg-Universität Mainz, Körperschaft des öffentlichen Rechts Markierungsvorläufer und Radiotracer zur nuklearmedizinischen Diagnose und Therapie von Prostatakrebs induzierten Knochenmetastasen
DE102022105175A1 (de) * 2022-03-04 2023-09-07 Atoms for Cure GmbH Markierungsvorläufer und Radiotracer mit drei oder mehr Targeting-Vektoren für die nuklearmedizinische Theranostik
CN119060093B (zh) * 2024-08-26 2025-09-05 广州医科大学附属第一医院(广州呼吸中心) 一种靶向成纤维细胞激活蛋白的抑制剂类放射性探针及其制备方法和应用
CN119060094B (zh) * 2024-08-26 2025-09-05 广州医科大学附属第一医院(广州呼吸中心) 一种靶向成纤维细胞激活蛋白的抑制剂类放射性探针及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE329623T1 (de) * 2001-10-22 2006-07-15 Dow Global Technologies Inc Radiopharmazeutishes mittel zur behandlung von krebs im frühstadium
EP1611119A1 (en) * 2003-04-03 2006-01-04 Semafore Pharmaceuticals, Inc. Pi-3 kinase inhibitor prodrugs
US7161000B2 (en) * 2003-05-30 2007-01-09 Sumitomo Chemical Company, Limited Method for producing phenol condensate
US10925977B2 (en) * 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
CN104774175B (zh) * 2007-06-26 2019-04-16 约翰·霍普金斯大学 标记的前列腺特异性膜抗原(psma)的抑制子、生物学评估及作为成像试剂的用途
JP5690733B2 (ja) * 2009-08-20 2015-03-25 富士フイルムRiファーマ株式会社 ビスホスホン酸誘導体及びその放射性金属核種標識体
CN103459573B (zh) * 2011-04-13 2015-11-25 弗门尼舍有限公司 用于控制加香醛和酮的释放的平衡动态混合物
ITMI20121156A1 (it) 2012-06-29 2013-12-30 Consiglio Nazionale Ricerche Metodo di elaborazione di immagini di tomografia a coerenza ottica
EP2862857A1 (en) * 2013-10-18 2015-04-22 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
MX377208B (es) 2015-07-07 2025-03-07 Five Eleven Pharma Inc Bifosfonatos de hbed, sus conjugados radio metalicos y su uso como agentes teranosticos.

Also Published As

Publication number Publication date
JP2018524352A (ja) 2018-08-30
KR20180026736A (ko) 2018-03-13
MX377208B (es) 2025-03-07
US20170022224A1 (en) 2017-01-26
WO2017007790A9 (en) 2018-01-04
DK3319643T3 (da) 2020-06-15
EP3319643A4 (en) 2019-04-10
CA2991498A1 (en) 2017-01-12
HK1254864A1 (en) 2019-07-26
EP3319643B1 (en) 2020-04-22
AU2016289474A1 (en) 2018-02-01
AU2016289474B2 (en) 2020-12-24
CN107847618A (zh) 2018-03-27
US10253052B2 (en) 2019-04-09
IL256726A (en) 2018-03-29
WO2017007790A1 (en) 2017-01-12
KR102651945B1 (ko) 2024-03-26
EP3319643A1 (en) 2018-05-16
AU2016289474C1 (en) 2021-04-08
EA201890221A1 (ru) 2018-06-29
CN107847618B (zh) 2021-07-16
MX2018000239A (es) 2018-05-23

Similar Documents

Publication Publication Date Title
JP6792875B2 (ja) Hbed−ビスホスホネート、その放射性金属コンジュゲート、およびセラノスティック剤としてのそれらの使用
JP6850027B2 (ja) イメージング及び治療のための尿素系前立腺特異的膜抗原(psma)阻害剤
KR102870722B1 (ko) 진단제 및 방사성핵종 치료제로서의 전립선-특이적 막 항원 (psma) 억제제
BR112020001785A2 (pt) radiotraçador e compostos radioterapêuticos bimodais
Suzuki et al. Synthesis and evaluation of a novel 68Ga-chelate-conjugated bisphosphonate as a bone-seeking agent for PET imaging
Srivastava et al. Synthesis and biological evaluation of newly designed phosphonate based bone-seeking agent
HK1254864B (en) Hbed-bisphosphonates and radiometal conjugates thereof, useful as theranostic agents
HK1248585A1 (en) Hbed-bisphosphonates, radiometal conjugates thereof and their use as theranostic agents
HK1248585B (zh) Hbed-二膦酸盐/酯、其放射金属轭合物和它们作为治疗诊断剂的用途
HK1255215B (en) Urea-based prostate specific membrane antigen (psma) inhibitors for imaging and therapy
KR20210083289A (ko) 스쿠아르산 연결을 갖는 표지 전구체

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190620

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190620

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200528

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200910

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201002

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201030

R150 Certificate of patent or registration of utility model

Ref document number: 6792875

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250